Prolonged Treatment Response to Pembrolizumab in a Patient with Pretreated Metastatic Colon Cancer and Lynch Syndrome
Joint Authors
Keating, Matthew
Giscombe, Lisa
Tannous, Toufic
Hartshorn, Kevan
Source
Case Reports in Oncological Medicine
Issue
Vol. 2019, Issue 2019 (31 Dec. 2019), pp.1-5, 5 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2019-09-02
Country of Publication
Egypt
No. of Pages
5
Main Subjects
Abstract EN
Pembrolizumab and other immunotherapies now play a prominent role in the treatment of metastatic colon cancer.
Clinicians have achieved significant response rates even in heavily pretreated patients, particularly those with mismatched repair deficiencies.
The endpoint of pembrolizumab treatment for patients who enjoy a strong response remains unclear.
Herein, we present the case of a 33-year-old man with pretreated metastatic colon cancer and a prolonged treatment response of over three years to single-agent pembrolizumab even after treatment discontinuation in July 2018.
Prior to pembrolizumab, he was found to have lung and liver metastases despite multiple lines of chemotherapy.
With pembrolizumab, there was a persistent downtrend in CEA level and uptrend in weight.
After nearly three years of pembrolizumab treatment from October 2015 through July 2018, PET scan showed no FDG-avid disease, and further treatment was placed on hold.
He remains under surveillance, with CT scan in February 2019 again showing no evidence of local or metastatic disease.
In patients whose treatment duration and disease course are not defined by toxicities/progressive disease but rather by sustained treatment responses, we propose that immunotherapy treatment duration be guided by close monitoring of CEA levels, weight, and clinical exams in addition to traditional imaging.
American Psychological Association (APA)
Keating, Matthew& Giscombe, Lisa& Tannous, Toufic& Hartshorn, Kevan. 2019. Prolonged Treatment Response to Pembrolizumab in a Patient with Pretreated Metastatic Colon Cancer and Lynch Syndrome. Case Reports in Oncological Medicine،Vol. 2019, no. 2019, pp.1-5.
https://search.emarefa.net/detail/BIM-1141932
Modern Language Association (MLA)
Keating, Matthew…[et al.]. Prolonged Treatment Response to Pembrolizumab in a Patient with Pretreated Metastatic Colon Cancer and Lynch Syndrome. Case Reports in Oncological Medicine No. 2019 (2019), pp.1-5.
https://search.emarefa.net/detail/BIM-1141932
American Medical Association (AMA)
Keating, Matthew& Giscombe, Lisa& Tannous, Toufic& Hartshorn, Kevan. Prolonged Treatment Response to Pembrolizumab in a Patient with Pretreated Metastatic Colon Cancer and Lynch Syndrome. Case Reports in Oncological Medicine. 2019. Vol. 2019, no. 2019, pp.1-5.
https://search.emarefa.net/detail/BIM-1141932
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1141932